Related Experiment Videos
Modulating conjunctival wound healing
M F Cordeiro1, L Chang, K S Lim
1Department of Pathology & Glaucoma, Moorfields Eye Hospital, London, UK.
Abstract:
Advances in molecular and cell biology have led to an expansion in our knowledge and understanding of the processes involved in wound healing. We review existing and potential therapies modulating the conjunctival scarring response, with particular reference to glaucoma filtration surgery. We discuss how the refinement of present antimetabolite regimens can minimise complications and improve surgical results, and advocate their use in carefully selected patient groups. Perhaps the most promising approach is targeting biological molecules. Hence, use of fully human neutralising monoclonal antibodies to the growth factor TGF beta has potential as a useful strategy for modifying conjunctival scarring. Combination therapies may also afford an improved therapeutic index. It is hoped that future therapies can offer safer, more specific, focal and titratable treatment, with far-reaching clinical applications.
Insights
New therapies targeting conjunctival scarring, including antimetabolites and monoclonal antibodies to TGF-beta, show promise for improving glaucoma surgery outcomes and minimizing complications.
Area of Science:
- Molecular and Cell Biology
- Ophthalmology
- Wound Healing Research
Background:
- Conjunctival scarring is a significant factor limiting the success of glaucoma filtration surgery.
- Advances in understanding wound healing processes offer new therapeutic targets.
Purpose of the Study:
- To review existing and potential therapies for modulating conjunctival scarring in glaucoma surgery.
- To explore novel strategies for improving surgical outcomes and minimizing complications.
Main Methods:
- Review of current literature on wound healing and conjunctival scarring.
- Analysis of antimetabolite regimens and their efficacy.
- Evaluation of biological therapies, including monoclonal antibodies targeting TGF-beta.
Main Results:
- Refinement of antimetabolite regimens can improve surgical results and reduce complications in selected patients.
- Fully human neutralizing monoclonal antibodies to TGF-beta represent a promising strategy for scar modification.
- Combination therapies may offer an improved therapeutic index.
Conclusions:
- Targeting biological molecules, particularly TGF-beta, holds significant potential for managing conjunctival scarring.
- Future therapies should aim for safer, more specific, focal, and titratable treatments.
- Optimized therapeutic approaches can lead to far-reaching clinical applications in glaucoma surgery.